Is the glucagon-like peptide-1 receptor agonist semaglutide able to alleviate mood in patients with major depressive disorder and overweight or obesity? Sema-Mood.

Status

Recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-511734-13-04

Enrollment

120

Registered

2025-05-07

Start date

2025-05-15

Completion date

Unknown

Last updated

2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unipolar depression Overweight and obesity, Obesity and overweight

Brief summary

The primary outcome will be change in Major Depression Inventory from baseline to end of study

Detailed description

Secondary outcomes include changes in body weight, hip and waist circumference, hemoglobin A1c lean and fat body mass and bone density, biomarkers related to inflammation, and oxidative stress and further overall functioning, quality of life, perceived stress, and cognitive scores

Interventions

DRUGWegovy 1 mg solution for injection in pre-filled pen

DRUGSaline Solution Basi 9 mg/ml solution for infusion

DRUGWegovy 0.5 mg solution for injection in pre-filled pen

DRUGWegovy 2.4 mg solution for injection in pre-filled pen

DRUGWegovy 1.7 mg FlexTouch solution for injection in pre-filled pen

DRUGWegovy 0.25 mg solution for injection in pre-filled pen

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Secondary

Measure	Time frame
Secondary outcomes include changes in body weight, hip and waist circumference, hemoglobin A1c lean and fat body mass and bone density, biomarkers related to inflammation, and oxidative stress and further overall functioning, quality of life, perceived stress, and cognitive scores	—

Primary

Measure	Time frame
The primary outcome will be change in Major Depression Inventory from baseline to end of study	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026